Free Trial

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories logo
$133.63 -0.96 (-0.71%)
Closing price 03:59 PM Eastern
Extended Trading
$133.64 +0.01 (+0.01%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
18

Based on 22 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for ABT.

Consensus Price Target

$145.39
8.80% Upside
According to the 22 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $145.39. The highest price target for ABT is $160.00, while the lowest price target for ABT is $130.00. The average price target represents a forecasted upside of 8.80% from the current price of $133.63.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
14 Buy rating(s)
9 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$145.39$144.47$143.11$124.33
Forecasted Upside8.80% Upside8.70% Upside7.32% Upside10.38% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside8.52% Upside1,399.92% Upside168.95% Upside
News Sentiment Rating
Positive News

See Recent ABT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/1/2025The Goldman Sachs Group
3 of 5 stars
 Boost TargetBuy$153.00 ➝ $157.00+16.35%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B)
7/18/2025Wells Fargo & Company
3 of 5 stars
Lower TargetOverweight$147.00 ➝ $142.00+14.26%
7/18/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$142.00 ➝ $141.00+13.29%
7/18/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$148.00 ➝ $145.00+20.08%
7/18/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$143.00 ➝ $145.00+20.08%
7/17/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy
7/16/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$130.00 ➝ $140.00+6.54%
7/15/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$145.00 ➝ $147.00+12.31%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$127.00 ➝ $137.00+3.75%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$140.00 ➝ $145.00+8.52%
6/16/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/16/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageMarket Perform$143.00+5.61%
4/17/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$133.00 ➝ $145.00+9.98%
4/17/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$158.00 ➝ $159.00+21.71%
4/17/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$135.00 ➝ $145.00+11.76%
3/10/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$133.00 ➝ $150.00+8.03%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$135.00 ➝ $160.00+15.20%
1/28/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
1/23/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$146.00 ➝ $148.00+25.68%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$133.00 ➝ $138.00+17.37%
10/8/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$130.00+14.69%
9/19/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOverweight$131.00+14.04%
7/30/2024Edward Jones
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:28 PM ET.


Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 3, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • The current stock price is around $131, which is near its 12-month high, indicating strong market performance and potential for further growth.
  • Abbott Laboratories has reported a significant year-over-year revenue increase of 7.4%, showcasing its ability to grow and adapt in the healthcare market.
  • The company has a solid net margin of over 32%, reflecting efficient operations and profitability, which can lead to higher returns for investors.
  • With a dividend yield of 1.8% and a payout ratio of 29.57%, Abbott Laboratories offers a reliable income stream for investors while maintaining a healthy balance for reinvestment.
  • Analysts have a consensus rating of "Moderate Buy" with a price target of approximately $145.39, suggesting that there is potential for stock appreciation based on expert evaluations.

Abbott Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • The price-to-earnings (P/E) ratio of 16.73, while reasonable, may indicate that the stock is not undervalued compared to its peers, which could limit upside potential.
  • Abbott Laboratories has a beta of 0.69, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Recent insider selling, including a significant transaction by the CFO, could raise concerns about the company's future performance and insider confidence.
  • Despite a strong revenue increase, the price-to-earnings-growth (PEG) ratio of 2.54 indicates that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
  • Market analysts have recently adjusted their price targets downward, which may signal a lack of confidence in the stock's short-term performance.

ABT Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $145.39, with a high forecast of $160.00 and a low forecast of $130.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 8.80% based on their 12-month stock forecasts.

Over the previous 90 days, Abbott Laboratories's stock had 2 upgrades by analysts.

Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ABT compares to other companies.


This page (NYSE:ABT) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners